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Hospital admissions for non-COVID-19 pathology have significantly reduced. It is believed that this 
may be due to public anxiety about acquiring COVID-19 infection in hospital and the subsequent 
risk of mortality. There is an urgent need for clarity regarding patients who acquire COVID-19 in 
hospital (nosocomial COVID-19 infection [NC]), their risk of mortality, compared to those with 
community acquired COVID-19 (CAC) infection.  
Methods 
The COPE-Nosocomial Study was an observational cohort study. The primary outcome was the 
time to all-cause mortality (estimated with an adjusted hazards ratio [aHR]), and secondary 
outcomes were Day-7 mortality and the time-to-discharge. A mixed-effects multivariable Cox’s 
proportional hazards model was used, adjusted for demographics and comorbidities. 
Results 
Our study included 1564 patients from 10 hospital sites throughout the UK, and one in Italy, and 
collected outcomes on patients admitted up to 28th April, 2020. 12.5% of COVID-19 infections were 
acquired in hospital. 425 (27.2%) patients with COVID died. The median survival time in NC 
patients was 14 days, which compared to 10 days in CAC patients. In the primary analysis, NC 
infection was associated with reduced mortality (aHR=0.71, 95%CI 0.51-0.99). Secondary 
outcomes found no difference in Day-7 mortality (aOR=0.79, 95%CI 0.47-1.31), but NC patients 
required longer time in hospital during convalescence (aHR=0.49, 95%CI 0.37-0.66).  
Conclusion  
The minority of COVID-19 cases were the result of NC transmission. Whilst no COVID-19 infection 
comes without risk, patients with NC had a reduced risk of mortality compared to CAC infection, 
however, caution should be taken when interpreting this finding. 
 
 
In the United Kingdom, authority to conduct the study was granted by the Health Research 
Authority (20/HRA/1898), and in Italy by the Ethics Committee of Policlinico Hospital Modena 
(Reference 369/2020/OSS/AOUMO). Cardiff University was the study sponsor.  
Keywords 










The novel coronavirus SARS-CoV-2 is implicated in causing the disease COVID-19 and its 
associated complications. While most infected people develop mild flu-like symptoms, some have 
significant respiratory complications and go on to develop multiorgan failure (1) and death (2). 
Despite robust infection control efforts, hospital-acquired (herein described as nosocomial) COVID-
19 infection have been reported (3 - 5). Heightened anxiety amongst the general public has 
resulted in individuals’ reluctance to attend hospital for diagnostic tests or treatments. This may 
account for the significant reduction in acute hospital attendances (6) and possibly contributed to 
the high excess mortality toll.  
 
The hallmark of SARS-CoV-2 is its highly contagious nature; it remains viable and infectious on 
surfaces for up to three days (7). Its main mode of transmission is through droplets and close 
contact with people with the disease (8). Incubation is estimated at 5-7 days (WHO), but this can 
take up to 14 days (9). Nosocomial infection is defined as an infection that is acquired in hospital 
by a patient who was admitted for a reason other than that infection (at least 15 days prior to a 
positive COVID-19 diagnosis), and in whom the pathogen was not incubating at the time of 
admission. Risk factors for developing a nosocomial infection include; age >70 years, 
immunosuppression, admission to intensive care, history of trauma, antibiotic use and use of an 
indwelling catheter (10). Prior to the current COVID-19 pandemic, nosocomial infections (most 
commonly from respiratory and urinary tracts and surgical wounds) already posed significant 
healthcare and economic burdens in both developed and resource-poor countries, with an average 
estimated prevalence of 8.7% worldwide (11). 
 
In general, nosocomial infections are not life threatening.  However, a large study in the United 
States reported that non-ventilator associated nosocomial pneumonia occurred in 2.1% of all 
hospital admissions, with a mortality rate of 13.1% (12). In addition, patients diagnosed with a 
nosocomial infection are likely to spend 2.5 times longer in hospital (13). SARS (Severe Acute 
Respiratory Syndrome, 2003) and the MERS (Middle East Respiratory Syndrome, 2012) had 
estimated nosocomial infection prevalence of 36% and 56% respectively (14). In comparison,  
Chinese estimates of the prevalence of nosocomial COVID-19 are as high as 41% (15-17). There 
is no current published data for nosocomial versus community acquired COVID-19 in UK hospitals, 
leaving uncertainty around morbidity or mortality and heightened public anxiety. A robust evidence 
base will help direct policy-makers and aid the dissemination of public health advice.  
 
The COPE (COVID-19 in Older People study) study was designed to assess a number of clinical 
parameters and biomarkers as prognostic tools for patients with COVID-19. The aim of this 
secondary study was to assess the burden of nosocomial COVID-19 (NC) infection and determine 
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if patients with NC exhibited poorer outcomes to those who experienced community acquired 





Data were obtained as part of a multi-centre international cohort study: the COPE study (COVID-
19 in Older People study), which assessed clinical and biomarkers as prognostic indicators of 
mortality. In the United Kingdom, authority to conduct the study was granted by the Health 
Research Authority (20/HRA/1898), and in Italy by the Ethics Committee of Policlinico Hospital 
Modena (Reference 369/2020/OSS/AOUMO). Cardiff University was the study sponsor. This 
manuscript follows the STROBE statement for reporting of cohort studies (18). Investigators at 
each site collated electronic and manual patient records. Prior to participating, all study personnel 
completed specific data collection training. Local policies on data protection were followed in order 
to record data securely at each site. Full study details can be found within the COPE protocol (19). 
 
Setting  
We utilised an established network of clinical teams with an interest in frailty from ten UK sites and 
one Italian site (www.opsoc.eu). The UK centres were Ysbyty Ystrad Fawr in Caerphilly, Royal 
Gwent Hospital in Newport, Nevill Hall Hospital in Abergavenny, University Hospital of Wales in 
Cardiff, Southmead Hospital in Bristol, Aberdeen Royal Infirmary, Royal Alexandra Hospital in 
Paisley, Inverclyde Royal Hospital, Salford Royal Hospital, and Glasgow Royal Infirmary. The 
Italian centre was the University Hospital of Modena Policlinico in Italy. All hospitals adhered to 
infection control guidelines with the application of appropriate personal protective equipment, 
isolation of suspected and confirmed cases, and had a policy of having no outside visitors during 
the period of data collection (20). All hospitals deliver urgent and emergency care to patients 
diagnosed with COVID-19. Data were collected from patients admitted with CVID from 27th 
February and 28th of April 2020. Further details of the study design are found within the protocol 
(19), and the main study findings are reported in the COPE study report (21). In the original 
protocol we estimated a 30% mortality in the frail, and 20% in those not frail (hazard ratio [HR] of 
0·60). In order to detect this difference with 80% power and with a 5% significance, at least 500 
patients were to be included. The sample size was increased to assess CFS categorised into four 





We attempted to include all consecutive patients admitted to hospital aged 18 years or older with a 
diagnosis of COVID-19. Diagnostic criteria were swabs confirming the presence of SARS-CoV-2, 
or a clinical diagnosis (made by the site clinical team and based on signs, symptoms and/or 
radiology) consistent with COVID-19. Patients were screened and excluded due to: not having a 
clinical (or laboratory) diagnosis; clinical documentation not available; or no available clinical 
resource for data capture. Clinical teams at each site screened in-patient admission lists for 
eligibility and had access to infection control records of positive COVID-19 laboratory testing. 
Screening logs of eligible participants were retained at each site.  
 
Outcomes: The primary outcome was the time-to-mortality from the date of admission (or date of 
diagnosis, if diagnosis was five or more days after admission). For example, all 196 NC patients 
were diagnosed 15 or more days after admission, and were analysed as the time from diagnosis to 
outcome (death or discharge). The 169 CAC were analysed from the date of diagnosis to outcome 
(since they had a positive diagnosis between five and 14 days after admission could not be 
confirmed as true NC), with the remaining 1199 CAC analysed as the difference from admission to 
outcome. The time to event was censored at death or discharge. 
Secondary outcomes: Day-7 mortality and the time-to-discharge (herein described as the length of 
stay).  
We collected variables with prognostic utility (1, 22-24) which included: patient age sex; C-reactive 
protein (CRP) on admission (; estimated glomerular filtration rate (eGFR) on admission; smoking 
status (never, previous, or current); frailty; and previous or current history of: coronary artery 
disease, diabetes mellitus, and hypertension. Frailty was measured using the pre-admission 
Clinical Frailty Score (CFS) representing a patients’ frailty two weeks prior to admission. The CFS 
is widely used within the UK to aid clinical management. The CFS is used as an ordinal 
hierarchical scale that numerically ranks frailty from 1 to 9, with a score of 1 being very fit, 2 well, 3 
managing well, 4 vulnerable, 5 mildly frail, 6 moderately frail, 7 severely frail, 8 very severely frail 
and 9 terminally ill. For the purposes of the analyses scores were grouped into a clinically 
meaningful groups: 1-2, 3-4, 5-6 and 7-9 (25).  
 
Data Analysis 
Baseline demographic and clinical characteristics were partitioned by mortality, and location of 
infection to describe the included participants.  
Time to mortality (primary outcome) and length of stay (secondary outcome) were analysed with 
mixed-effects multivariable Cox’s proportional baseline hazards regression models. The analyses 
were fitted with a random effect to account for hospital variation (26), and adjusted for the base 
model of: patient age group; sex; smoking status; CRP; diabetes; hypertension ; coronary artery 
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disease; and the CFS. The adjusted hazard ratios (aHR) were estimated with associated 95% 
confidence intervals (95%CI). The baseline proportionality assumption was tested visually with log-
log residuals. Each time to event analysis was reported with a Kaplan Meier survival plot.  
The secondary outcome of Day-7 was analysed using a mixed-effects multivariable logistic model, 
fitting each hospital as a random intercept effect, and adjusted with covariates consistent with the 
primary outcome. The adjusted odds ratio (aOR) were estimated and presented with associated 
95%CI. Missing data were explored for patterns of missingness. The primary outcome analysis 
was repeated within each of the co-morbidity subgroups to assess the impact of NC within each 
subgroup. Analysis was carried out using Stata version 15 (27). Kaplan Meier survival plots were 
generated in R (28). 
 
Results  
The COPE study screened 1,687 participants from general medical, surgical, geriatric, respiratory, 
and infectious diseases wards, as well as intensive care units where applicable. These wards 
solely managed suspected or confirmed COVID-19 patients. 143 patients were excluded from the 
study after screening, with the remaining 1,564 participants included. There were 1410 (90.2%) 
patients from the UK, and 154 (9.8%) from Italy (Table 1). Most were diagnosed laboratory testing 
(95.1%) and 64 (4.9%) by clinical diagnosis. Data quality was high and a complete case dataset 
was obtained for over 97% of included patients. There were 25 cases of missing smoking status, 
which were imputed as never smokers, and 32 cases of missing CRP, which were median 
imputed. Other missing covariates occurred in no more than 14 patients. Given the minimal degree 
of missing data, the complete case population was used within each analysis, and the number 
included shown as the population under investigation. 
 
Descriptive data  
The median patient age was 74 years old (IQR, 61-83), and 903 were male (57.7%). The overall 
in-hospital COVID-19 mortality rate was 27.2% (425/1564), and this varied throughout the 11 
hospitals between 12.2% and 43.9%. Of all hospital episodes of COVID-19 infection, we found 
12.5% were NC (196/1564) and 87.5% were CAC (1368/1564).  The median proportion of NC 
infections from the total number of COVID-19 cases from the 11 hospitals was 8.7% (IQR, 3.0-
14.1%). The median number of days between patient admission and a positive COVID-19 test for 
NC infection was 32.5 days (IQR, 23-54 days), and for CAC the median was 0 days (IQR, 0-1 
days). The median patient age for NC infection was 80 years old (IQR, 71.5-86.5 years), and was 
73 years old (IQR, 60-82 years) for patients with CAC infection (Supplementary Table 1). The 
median level of frailty was moderately frail [CFS=6] for NC, and vulnerable [CFS=4] for CAC. Full 





By end of study period, 27.0% of patients with NC were dead versus 27.2% CAC patients. The 
median time-to-mortality was 14 days in the NC versus 10 days in the CAC group (Figure 1). In the 
multivariable analysis we found that NC infection was associated with reduced mortality 
(aHR=0.71, 95%CI 0.51-0.99; p=0.04, Table 2). It was also found that increased mortality was 
associated with: older age (compared to under 65, aged 65-79, aHR=2.70, 95%CI 1.91-3.81, 
p<0.001; aged ≥80, aHR=3.30, 95%CI 2.28-4.78, p<0.001); increased frailty (CFS=3-4, aHR=1.67, 
95%CI 1.07-2.60, p=0.02; CFS=5-6, aHR=2.08, 95%CI 1.31-3.31, p=0.002; CFS=7-9, HR=2.75, 
95%CI 1.73-4.38, p<0.001), renal failure (aHR=1.32; 1.07-1.63) and increased CRP (aHR=1.004, 
95%CI 1.003-1.005, p<0.001) [Table 2]. 
In multivariable analysis for Day 7 mortality, there was no association between NC infection and 
mortality (aOR=0.89, 95%CI 0.60-1.34, p=0.59, Table 3. Important factors associated with Day 7 
mortality were: increased age (compared to under 65, aged 65-79, aOR=3.12, p<0.001; aged ≥80, 
aOR=3.99, p<0001); increased CRP (aOR=1.006, p<0.001); reduced renal function (eGFR<60, 
aOR=1.95, p<0.001); CAD (aOR=1.59, p=0.01); and increased frailty (compared to CFS1-2: CFS 
7-9, aOR=3.62,  P<0.001). 
Median length of stay for CAC patients was half that of NC patients (16 days versus 33 days, 
aHR=0.49, 0.37-0.66, p<0.001, Table 3). Covariates associated with an increased length of stay 
for all patients were: increased age (compared to under 65, aged 65-79, aHR=0.80; aged ≥80, 
aHR=0.61, p<0.001); worsening frailty (compared to CFS1-2, CFS 5-6, 0.73, p=0.02; CFS 7-9, 
aHR=0.70, p=0.02); and elevated CRP (aHR= 0.997, p<0.001). 
The multivariable mixed effects Cox regression exploratory analyses of the time-to-mortality show 
consistent findings for NC versus CAC within each of the demographic and comorbidity subgroup 




Statement of principal findings 
This study is the first to report outcomes for patients with NC infection. Of all COVID-19 cases 
included 12.5% of infections were due to transmission in hospital. Overall mortality rate was 27.2% 
with a reduction in mortality with an NC infection. Patients with NC infection experienced a longer 
length of stay in hospital.   
 
The strengths and weaknesses of the findings in relation to other studies 
The proportion of nosocomial infections with COVID-19 found within this study was lower than the 
41% previously reported by Wang and colleagues (15). Although direct comparisons are difficult, 
Wang had a small sample size (total 138 patients) which included healthcare worker infections. 
Excluding these, the rate of patient NC infection was similar to our study (12.3% versus 12.5%).  
 
9 
Compared to other reported rates of NC infection during historical global pandemics, it appears 
that NC infection rates are much lower during the COVID-19 pandemic, with the majority of in-
hospital COVID cases originating from the community.  
 
In western healthcare, infection control policies have been developed for many years which have 
positively impacted the response to the rapidly evolving pandemic situation.  This multicentre study 
is predominantly UK based and it is important to recognise that data from eastern populations may 
not be applicable to western populations based upon individual genetic differences, available 
healthcare resources and preparedness of healthcare providers to respond to overwhelming 
demands on services.  The first COVID-19 positive patient was reported to the World Health 
Organisation (WHO) on 31st December in Wuhan, China. The UK and Italy reported their first 
cases on 31st January 2020.   It is possible that countries affected later were able to anticipate 
resources required and recognised the importance of being able to implement those plans quickly 
and have a different NC rate. This allowed patients with either diagnosed or suspected to have 
COVID-19 to be isolated, managed with an increased awareness of cross infection, with 
preventative measures such as personal protective equipment, in dedicated ‘COVID-19’ wards.  
 
The public health message during the United Kingdom’s lockdown was to stay at home, leaving 
home only for essential travel, in order to maintain social distancing measures.  Understandably 
there is much anxiety amongst the general public, particularly amongst those with pre-existing 
healthcare conditions.  This has led to 29% fewer ED attendances reported in March 2020 
compared to March 2019 in England alone (29).  Furthermore, the Office for National Statistics 
(ONS) reported the highest death rate in England & Wales since 2000 (week ending 3rd April 
2020), 6,082 more than the 5-year average. Worryingly only 3,475 of these are attributed to 
COVID-19 (30), raising the concern that these additional deaths may have been related to a public 
reluctance to seek medical attention. Our findings have demonstrated that mortality rates are no 
worse if COVID-19 was acquired in hospital, compared with those who have acquired the disease 
in the community. Highlighting that patients should be reassured when seeking medical attention 
for non-COVID-19 conditions.  
 
This NC group of patients were older and frailer, with a non COVID-19 pre-existing reason for 
hospital admission, all leading to and a median hospital stay in excess of one month. With daily 
inpatient assessment it is likely that prompt recognition of COVID-19 like symptoms occurred 
leading to prompt laboratory and clinical diagnosis of COVID-19 infection. In contrast the CAC 
patients may have tolerated their symptoms at home for a period of time before requiring hospital 
admission. There is also a possibility that reluctance to seek medical attention may have 
compounded their potentially delayed presentation to hospital. This difference in clinical 
management may have led to the NC patients to have timely supportive treatment, as opposed to 
 
10 
those coming in from home who may have presented late with more severe illness led to a 
reduced mortality in the CAC patients. It is possible that normal targeted and individualised care for 
longer term patients were reconfigured to focus on acute admission assessment and critical care.  
Although not assessed in this study and difficult to assess objectively, the influence of nursing in 
isolation and prohibition of hospital visitors is likely to have had a negative psychological impact for 
this patient group.   
 
Strengths and weaknesses of the study 
This is a large multicentre observational cohort study including over 1,500 adult in patients. Our 
definition of NC was conservative, so the infection rate should be considered 12.5% or greater. 
Since hospital workers or patient visitors with COVID-19 were not included in the definition of NC 
infection, or were patients with a positive diagnosis less than 15 days prior to their admission. Or 
asymptotic patients were discharged without a positive diagnosis (most likely in younger or less 
severe patients). A further limitation of this observational study is that we could not allow for case-
mix differences between the NC and CAC groups, including mildly symptomatic or asymptomatic 
patients diagnosed COVID-19 as part hospital screening programmes. Furthermore, we did not 
assess the cause of death for patients from both NC and CAC groups, although it is assumed that 
COVID-19 formed at least part of the cause of death for all those who died. 
 
Impact on clinical practice, public health and policymakers  
With low hospital acquired infection rates, this study demonstrates that effective infection control 
policies are in place in western hospitals. It is now the responsibility of public and professional 
bodies to actively encourage patients to seek acute medical attention when required and to 
consider the risks and benefits of reintroducing elective services. Organisational response to 
emerging evidence should be proactive, considered and continuous. It is imperative that 
complacency is avoided in response to reduced published daily mortality figures in order to prevent 
a second wave.  
 
Conclusion  
In a large study, we found that the minority of COVID-19 hospital episodes were the result of 
nosocomial transmission. Whilst no COVID-19 infection comes without risk, those patients with NC 
infection had no greater risk of mortality, and potentially lower risk than people admitted to hospital 
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Table 1 Demographics, frailty and nosocomial infection, by mortality 
 
 Dead Alive Total 
Sites& 425 (27.2%) 1,139 (72.8%) 1,564 
    
Hospital A 15 (13.0) 100 (87.0) 115 (7.4) 
Hospital B 14 (28.0) 36 (72.0) 50 (3.2) 
Hospital C 34 (22.2) 119 (77.8) 153 (9.8) 
Hospital D 10 (23.3) 33 (76.7) 43 (2.8) 
Hospital E 15 (12.2) 108 (87.8) 123 (7.9) 
Hospital F 23 (14.9) 131 (85.1) 154 (9.9) 
Hospital G 36 (32.1) 76 (67.9) 112 (7.2) 
Hospital H  108 (43.9) 138 (56.1) 246 15.7) 
Hospital I 126 (33.2) 254 (66.8) 380 (24.3) 
Hospital J 43 (24.0) 136 (76.0) 179 (11.5) 
Hospital K 1 (11.1) 8 (88.9) 9 (0.6) 
    
Age    
Under 65 yrs 55 (11.3) 433 (88.7) 488 (31.2) 
65 to 79 yrs 168 (31.4) 367 (68.6) 535 (34.2) 
Over 80 yrs 202 (37.3) 339 (62.7) 541 (34.6) 
    
Sex    
Female 170 (25.7) 491 (74.3) 661 (42.3) 
Male 255 (28.2) 648 (71.8) 903 (57.7) 
    
Smoking Status    
Never smokers 205 (25.2) 609 (74.8) 814 (52.9) 
Ex smokers 185 (30.7) 418 (69.3) 603 (39.2) 
Current smokers 26 (21.5) 95 (78.5) 121 (7.9) 
Missing 9 17 26 
    
CRP&& 113, (64-185) 71, (30-137) 83, (37-153) 
    
eGFR > 40    
No 202 (20.6) 778 (79.4) 980 (63.2) 
Yes 217 (38.1) 353 (61.9) 570 (36.8) 
Missing 6 8 14 
    
Hypertension    
No 184 (24.4) 571 (75.6) 755 (48.4) 
 
15 
Yes 238 (29.6) 566 (70.4) 804 (51.6) 
Missing 3 2 5 
    
Coronary Artery disease    
No 290 (23.9) 924 (76.1) 1214 (77.9) 
Yes 132 (38.3) 213 (61.7) 345 (22.1) 
Missing 3 2 5 
    
Diabetes     
No 295 (25.8) 849 (74.2) 1144 (73.2) 
Yes 128 (30.8) 287 (69.2) 415 (26.6) 
Missing 2 3 5 
    
COVID-19 Infection    
Community acquired 372 (27.2) 996 (72.8) 1368 (87.5) 
Nosocomial acquired 53 (27.0) 143 (73.0) 196 (12.5) 
    
Clinical Frailty Score (CFS)    
1, Very Fit 7 (7.7) 84 (92.3) 91 (5.8) 
2, Fit 22 (11.2) 175 (88.8) 197 (12.6) 
3, Managing well 55 (19.2) 232 (80.8) 287 (18.4) 
4, Vulnerable 52 (28.1) 133 (71.9) 185 (11.9) 
5, Mildly frail 50 (27.5) 132 (72.5) 182 (11.7) 
6, Frail 84 (33.5) 167 (66.5) 251 (16.1) 
7, Severely frail 96 (36.9) 164 (63.1) 260 (16.7) 
8, Very severely frail 44 (55.7) 35 (44.3) 79 (5.1) 
9, Terminally ill 12 (44.4) 15 (55.6) 27 (1.7) 
Missing 3 2 5 
 





Table 2 – Primary outcome: Crude and Adjusted Time-to-mortality, from admission (or diagnosis, 
for patients with a diagnosis five or more days after admission). Survival is estimated with a crude 
hazard ratio (HR), and adjusted Hazards Ratio (aHR), using a crude and adjusted mixed-effects 
multivariable Cox proportional hazards regression. 
 
 Crude Hazard ratio (HR) Adjusted HR (aHR)& 
 (n=1,520)&& (n=1,500)&&& 
 HR, (95%CI) p-value aHR, (95%CI) p-value 
Location infection acquired     
Community acquired (Ref) Reference Category Reference Category 
Hospital acquired 0.71, (0.52-0.97) 0.03 0.71, (0.51-0.98) 0.04 
Age     
Under 65 Reference Category Reference Category 
65 to 79 3.30, (2.40-4.55) <0.001 2.70, (1.91-3.81) <0.001 
Over 80 4.05, (2.95-5.57) <0.001 3.30, (2.28-4.78) <0.001 
Sex (Female) Reference Category Reference Category 
Male 0.99, (0.81-1.21) 0.93 1.10, (0.89-1.37) 0.38 
Smoking status (Never) Reference Category Reference Category 
Ex-smokers 1.20, (0.98-1.47) 0.08 0.95, (0.76-1.17) 0.61 
Current smokers 0.84, (0.55-1.29) 0.43 1.09, (0.70-1.70) 0.71 
CRP$  1.003, (1.002-1.004) <0.001 1.004, (1.003-1.005) <0.001 
Patients with diabetes 1.12, (0.90-1.39) 0.30 1.03, (0.82-1.30) 0.77 
Patients with CAD 1.57, (1.26-1.95) <0.001 1.21, (0.96-1.53) 0.10 
Patients with hypertension 1.24, (1.01-1.51) 0.04 0.98, (0.80-1.22) 0.89 
Patients with reduced renal 
function 
  
1.93, (1.58-2.35) <0.001 1.32, (1.07-1.63) 0.01 
Clinical Frailty Scale     
CFS 1 to 2 Reference Category Reference Category 
CFS 3 to 4 2.25, (1.47-3.45) <0.001 1.67, (1.08-2.60) 0.02 
CFS 5 to 6 3.12, (2.05-4.76) <0.001 2.08 (1.31-3.32) 0.002 
CFS 7 to 9 4.41, (2.90-6.71) <0.001 2.75, (1.73-4.38) <0.001 
 
&The multivariable mixed-effects Cox regression was adjusted for: age group; sex; smoking; CRP; diabetes; CAD; hypertension; and the 
Clinical Frailty Scale 
&&44 Cases were not included in the analysis due to patient death on admission. 
&&&20 Cases were not included in the analysis due to missing covariate data-see Table 1. 





Table 3: Secondary Outcomes. Outcome 1: Day-7 mortality (Left panel), estimated with an 
adjusted Odds Ratio (aOR) and analysed using an adjusted mixed-effects multivariable logistic 
model. Outcome 2: Length of hospital stay (Right panel) (measured as the time to discharge from 
admission, or diagnosis for patients with a diagnosis five or more days after admission), estimated 
with an adjusted Hazards Ratio (aHR) and analysed with an adjusted mixed-effects multivariable 
Cox proportional hazards regression. 
 
 Day 7 Mortality Length of Hospital Stay 
 Adjusted Odds ratio (aOR) Adjusted HR (aHR)& 
 (n=1,494)&& (n=1,500)&&& 
 HR (95%CI) p-value aHR (95%CI) p-value 
Location infection acquired     
Community acquired (Ref) Reference Category Reference Category 
Nosocomial 0.79 (0.47-1.31) 0.35 0.49 (0.37-0.66) <0.001 
Age   
Under 65 Reference Category Reference Category 
65 to 79 3.12 (1.83-5.33) <0.001 0.80 (0.66-0.97) 0.03 
Over 80 3.99 (2.25-7.08) <0.001 0.61 (0.48-0.78) <0.001 
Sex (Female) Reference Category Reference Category 
Male 1.13 (0.80-1.58) 0.50 093 (0.79-1.09) 0.36 
Smoking status (Never) Reference Category Reference Category 
Ex-smokers 1.09 (0.78-1.53) 0.61 0.97 (0.82-1.14) 0.70 
Current smokers 0.98 (0.49-1.99) 0.96 1.03 (0.76-1.41) 0.83 
CRP$  1.01 (1.005-1.008) <0.001 0.997 (0.996-0.998) <0.001 
Patients with diabetes 1.00 (0.69-1.44) 0.99 0.94 (0.78-1.13) 0.50 
Patients with CAD 1.59 (1.11-2.28) 0.01 1.09 (0.89-1.35) 0.39 
Patients with hypertension 0.86 (0.61-1.21) 0.38 0.91 (0.77-1.07) 0.24 
Patients with reduced renal 
function 
  
1.95 (1.39-2.73) <0.001 0.91 (0.76-1.09) 0.32 
Clinical Frailty Scale     
CFS 1 to 2 Reference Category Reference Category 
CFS 3 to 4 1.28 (0.65-2.52) 0.48 0.94 (0.77-1.16) 0.58 
CFS 5 to 6 1.86 (0.91-3.79) 0.09 0.73 (0.56-0.96) 0.02 
CFS 7 to 9 3.62 (1.78-7.34) <0.001 0.70 (0.53-0.94) 0.02 
& The multivariable mixed-effects logistic and cox regressions were adjusted for: age group; sex; smoking; CRP; diabetes; CAD; 
hypertension; and the Clinical Frailty Scale 
&& 6 cases were excluded from the analysis as the patient was followed up for less than 7 Days and alive and in hospital 












Figure 2: Kaplan Meier Survivor Plot for time–to–discharge for nosocomial verses 







Supplementary Figure 1: Time to mortality analysis, carried out in each subgroup. The findings 
present the adjusted multivariable Hazard Ratio for patients with a Nosocomial Infection versus a 
Community acquired COVID-19 infected patients 
 
Note:  Multivariable analyses adjusted for age group, sex, smoking status, hypertension, 
diabetes, CAD, kidney function, CRP and CFS. *Subgroup omitted due to low number of 
observations. 
